Montreal, QC – July 26, 2004 – Biopharmaceutical company Celmed BioSciences says it has made four key appointments to its board of directors. Pierre Marc Johnson, already a director of the company, will assume the responsibilities of chairman of the board.
Mr Johnson, lawyer and physician, former Premier of Quebec, has been of counsel to Heenan Blaikie since 1996.
Monique Lefebvre, PhD, joins Celmed’s board. She is also a director of Transcontinental GTCL, ART Advanced Research Technologies and Desjardins Financial Security.
Roger L Headrick, formerly chairman of the board of NewBiotics. recently acquired by Celmed, brings more than 30 years of executive management experience in finance and strategic planning.
Martijn Kleijwegt, managing partner of Life Sciences Partners, has gained extensive experience in the life sciences sector as general partner of Euroventures Benelux, European venture capital fund based in the Netherlands.
Martial Lacroix, PhD, is vice president of GeneChem Therapeutics Ventures Fund. Prior to this, Dr Lacroix was a co-founder of BioChem Pharma and acted as director of technology transfer. From 1986 to 1995, he held a number of positions with BioChem ImmunoSystems, including director of research and development and director of quality control. Between 1981 and 1986, Dr Lacroix was a professor-scientist in the department of virology at Institut Armand-Frappier. Dr Lacroix received bachelors and masters degrees in biochemistry from University of Montreal and a PhD from the University of Toronto. Dr Lacroix has authored 33 scientific publications and holds 8 issued patents.
The five other members are Andr de Villers, MD, president and chief executive officer, Celmed BioSciences, Thierry Abribat, PhD, DVM, executive vice president, business development, Theratechnologies, Grald Andr, Eng, PhD, vice president, corporate development, Theratechnologies, Gatan Gravel, portfolio manager, life sciences, Solidarity Fund QFL, Martin Saint-Jean, development manager, SGF Sant.